Gram Research analysis of a 2026 review finds that potent topical corticosteroids remain highly effective for both atopic dermatitis and psoriasis. In eczema, tacrolimus 0.1% and topical JAK inhibitors also rank among the most effective treatments, while roflumilast and tapinarof offer effective non-steroid options for psoriasis.
Eczema and psoriasis are long-lasting skin conditions that can make daily life hard. A 2026 review published in the journal Therapie looked at the creams, ointments, and gels used to treat them. According to research reviewed by Gram, the review found that potent topical corticosteroids, a common type of anti-inflammatory cream, remain highly effective for both conditions. For eczema, tacrolimus 0.1% and newer topical JAK inhibitors also rank among the strongest options. For psoriasis, roflumilast and tapinarof have shown good results in recent large trials as non-steroid choices. The authors also stressed that how well a treatment works depends on more than the medicine itself. The cream’s base, how often it must be applied, and whether people actually use it all matter. Children need extra care, since most research on them is still limited. This review summarizes existing studies rather than running a new experiment, so its conclusions depend on the quality of the research it draws from.
Key Statistics
A 2026 review published in the journal Therapie found that potent topical corticosteroids remain highly effective treatments for both atopic dermatitis and psoriasis.
A recent network meta-analysis summarized in a 2026 review reported that tacrolimus 0.1% and topical JAK inhibitors rank among the most effective options for atopic dermatitis across several clinical outcomes.
According to a 2026 review, roflumilast and tapinarof were established as effective non-steroid treatments for psoriasis in recent phase 3 trials.
The Quick Take
- What they studied: The researchers asked which skin creams and ointments work best for eczema (atopic dermatitis) and psoriasis, how well people stick with them, and what parents and doctors should watch for when treating children.
- Who participated: This was not a new study with its own group of patients. The authors reviewed earlier studies, including trials and a recent network meta-analysis, which combines results from many studies. The total number of people across those studies was not stated in the paper.
- Key finding: Strong steroid creams remain among the most dependable treatments for both conditions. In eczema, tacrolimus 0.1% and topical JAK inhibitors ranked among the most effective options, while PDE4 inhibitors generally worked less well.
- What it means for you: If you have mild to moderate eczema or psoriasis, a topical treatment is often the first choice. Talk with a doctor or dermatologist about which cream fits your condition, your age, and your daily routine. Using the treatment as directed matters as much as which one you pick.
The Research Details
This paper is an overview, sometimes called a narrative review. Instead of testing people directly, the authors gathered and summarized what is already known about creams and ointments used on the skin for eczema and psoriasis. They looked at older treatments such as steroid creams and vitamin D creams, along with newer medicines that work on specific parts of the immune system.
The review drew heavily on meta-analyses, which are studies that pool results from many earlier trials to look for overall patterns. It also covered recent phase 3 trials, which are the large final-stage studies that test whether a medicine works and is safe before approval. Together, these sources were used to compare how well different treatments work.
The authors also considered factors beyond the medicine itself, such as the cream’s base (for example, an ointment versus a lotion), how many times a day it must be applied, patient education, and how the product feels and looks on the skin. They noted that children are often treated with creams based on adult studies, which is an important limitation discussed further below.
This is a published review in a peer-reviewed journal, which means outside experts checked the work before publication. Its strength comes from drawing on several well-known studies and recent large trials. Its main weakness is that it summarizes earlier research rather than generating new data, so its conclusions are only as strong as the studies it relies on. The paper does not give a single total number of participants, so readers cannot judge overall sample size from this summary alone.
What the Results Show
The clearest result is that potent topical corticosteroids, which are strong steroid creams, remain highly effective for both atopic dermatitis and psoriasis. These creams have been used for decades and continue to be a foundation of treatment. Their strength lies in how reliably they calm inflammation and reduce itching and redness.
For eczema, the review reports that recent network meta-analysis data place potent steroid creams, tacrolimus 0.1%, and topical JAK inhibitors among the most effective choices across several measures of improvement. Tacrolimus is a non-steroid cream that works by calming the immune response in the skin. JAK inhibitors are newer medicines that block specific signals in the immune system. In contrast, PDE4 inhibitors generally showed lower effectiveness for eczema.
For psoriasis, the review notes that older evidence supports potent steroid creams, especially when they are combined with vitamin D analogues, which are vitamin D-based creams that slow skin cell overgrowth. Recent phase 3 trials established roflumilast and tapinarof as effective non-steroid options. Evidence for topical JAK inhibitors in psoriasis is still more limited.
The authors also emphasized that effectiveness in everyday life depends on factors beyond the active medicine. Adherence, meaning how consistently people use their treatment, strongly shapes real-world results. It is influenced by the cream’s base, how much work the routine feels like, education, and how acceptable the product is to use on visible skin.
The review highlights that children need special attention. Topical therapy is especially important for young patients, yet comparisons between treatments in children are limited and often borrowed from adult studies. Children’s skin absorbs medicine differently, and the body can take in more of a cream relative to its size. This means doctors must weigh possible side effects, including local irritation and, in some cases, medicine entering the bloodstream.
The authors also call for future research that looks at more than the active ingredient. They want studies to examine formulation, adherence, patient preferences, long-term safety, and consistent ways of measuring results. These steps would make comparisons between treatments more useful to real patients and their families.
The review fits with the existing understanding that topical steroids are a first-line choice for mild to moderate skin disease. It builds on newer evidence from network meta-analyses in eczema and recent phase 3 trials in psoriasis, which have added non-steroid options to the toolbox. The findings also echo a growing recognition that a cream’s base and the patient’s willingness to use it can determine whether a treatment succeeds.
The review does not present new patient data, so it cannot confirm results through its own experiments. Some conclusions, especially those about children, rely on studies done in adults, which may not apply equally to younger people. The paper also does not give one clear overall number of participants or a single set of results that combines everything, which makes it harder to judge the size of each effect. Finally, evidence for some newer treatments, such as topical JAK inhibitors in psoriasis, is still limited.
The Bottom Line
Research shows that potent topical corticosteroids remain highly effective for both eczema and psoriasis, so they are still a standard starting point for mild to moderate disease (high confidence). For eczema, tacrolimus 0.1% and topical JAK inhibitors appear to be among the most effective options (moderate confidence, based on network meta-analysis data). For psoriasis, roflumilast and tapinarof are effective non-steroid choices that may suit people who want to avoid steroids (moderate confidence). Choosing a treatment should also consider the cream’s base, how often it must be used, and personal preference (high confidence that these factors matter).
People with mild to moderate eczema or psoriasis, parents of children with these conditions, and anyone deciding between topical treatments with a doctor should find this useful. Readers with severe disease, which may need oral or injected medicines, should look beyond this review. Anyone who is pregnant or has other health conditions should check with a clinician before changing treatment.
Topical steroids often ease itching and redness within days to a couple of weeks when used as directed. Newer non-steroid creams may take several weeks to show their full effect, and results vary from person to person. Long-term control usually depends on steady use and regular check-ins with a clinician, rather than a quick fix.
Frequently Asked Questions
What is the best cream for eczema according to recent research?
Potent topical corticosteroids, tacrolimus 0.1%, and topical JAK inhibitors rank among the most effective options for atopic dermatitis in recent network meta-analysis data. PDE4 inhibitors generally showed lower effectiveness. The best choice depends on your age, severity, and how well you tolerate the treatment.
Are non-steroid creams good for psoriasis?
Recent phase 3 trials established roflumilast and tapinarof as effective non-steroid treatments for psoriasis. Potent steroid creams, especially when combined with vitamin D analogues, have long-standing support. Evidence for topical JAK inhibitors in psoriasis remains more limited than for other options.
Why does it matter whether I actually use my eczema or psoriasis cream?
Adherence is a major factor in real-world results, according to a 2026 review in Therapie. Cream base, treatment burden, education, and how the product feels on the skin all influence whether people keep using it. A well-chosen treatment works best when applied consistently as directed.
Are topical treatments safe for children with eczema or psoriasis?
Topical therapy is especially important for children, but comparative research in young patients is limited and often based on adult studies. Children’s skin can absorb more medicine relative to body size. Doctors weigh local irritation and possible absorption into the bloodstream when prescribing creams for kids.
Want to Apply This Research?
- Log each application of your topical treatment, noting the time of day, the amount used, and the body area treated. Rate your itch and skin appearance on a simple 0 to 10 scale each day to see patterns over time.
- Set daily reminders for your cream, especially at times you are most likely to forget, such as after a shower or before bed. Keep your treatment somewhere visible and pair it with an existing habit, like brushing your teeth.
- Review your logs every two to four weeks and share the summary with your doctor or dermatologist. Track any side effects such as stinging, thinning skin, or irritation, and note any changes in flare frequency over several months. Use these records to decide whether a treatment is working or whether a different option should be discussed.
This article summarizes a review of existing research on topical treatments for eczema and psoriasis. It is for general information only and is not medical advice. Skin treatments can have side effects and may not suit everyone, especially children, pregnant people, or those with other health conditions. Talk with a doctor or dermatologist before starting, stopping, or changing any treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.